GH Peptides & HGH in BC — What's Legal, What Works, and Where to Get It (2026)
Quick Answer
GH peptides such as Sermorelin, Ipamorelin, and CJC-1295 do not hold Drug Identification Numbers (DINs) in Canada and are classified as unauthorized drugs by Health Canada as of April 2026. Human growth hormone (somatropin) is legally available in BC only for specific approved indications including adult growth hormone deficiency, and requires a prescription from a licensed physician plus dispensing through a licensed pharmacy. If you are considering growth hormone optimization therapy in British Columbia, consult a qualified healthcare professional to discuss legal, evidence-based options and use the BCMedicalAccess.ca directory to find appropriate clinics.
Last Updated: May 26, 2026
Reviewed by Sarah K., MSc Health Sciences | BCMedicalAccess.ca Editorial Team
⚠️ Important Notice
This article is for informational purposes only and does not constitute medical advice. BCMedicalAccess.ca is a healthcare navigation resource, not a medical provider. Consult a licensed physician before pursuing any hormone or peptide therapy.
Introduction
Few categories of longevity medicine generate more confusion in BC than growth hormone optimization. The reader has heard about Sermorelin from a podcast, seen Ipamorelin/CJC-1295 advertised by a Vancouver wellness clinic, and likely encountered "research peptide" suppliers shipping injectables straight to a residential address. Somewhere in the same conversation, human growth hormone (HGH) gets mentioned, usually with claims that mix legitimate adult GHD treatment with anti-aging marketing.
The legal landscape is genuinely confusing, and it changed materially in April 2026. Health Canada has now issued two separate advisories, April 2025 and April 2026, naming specific peptides as unauthorized drugs, and provincial colleges of physicians have begun publishing guidance to clinicians [1,2]. What was a regulatory grey zone is becoming substantially less grey, particularly for the GH peptides this article covers.
This guide is informational, not medical advice. It explains what these substances are, what the human evidence shows, what's legal in BC right now, and what the legitimate access pathways look like.
What Are GH Peptides? (vs. HGH)
The growth hormone (GH) axis is straightforward: the hypothalamus releases growth hormone-releasing hormone (GHRH), which signals the pituitary to release growth hormone, which signals the liver to produce insulin-like growth factor-1 (IGF-1), which mediates most of GH's downstream effects. Two intervention strategies exist.
Growth hormone secretagogues are peptides that stimulate the pituitary to release more of your own growth hormone. They work upstream, preserving the natural pulsatile release pattern and the body's negative-feedback loops. Exogenous HGH (somatropin) is recombinant human growth hormone administered directly. It bypasses the hypothalamus and pituitary entirely, delivering a flat, non-pulsatile concentration of GH.
The choice between them is not stylistic. Secretagogues tend to produce smaller, more physiological IGF-1 elevations. Exogenous HGH produces larger elevations and stronger effects, but with greater risk of suppressing endogenous production and a higher side-effect profile.
| Compound | Class | Mechanism | Health Canada status |
|---|---|---|---|
| Sermorelin | Secretagogue (GHRH analog, 29 aa) | Stimulates pituitary GH release | No DIN; original Geref discontinued |
| Ipamorelin | Secretagogue (selective ghrelin agonist) | Triggers GH pulse without raising cortisol/prolactin | No DIN; named in April 2026 advisory |
| CJC-1295 | Secretagogue (long-acting GHRH analog) | Sustained GHRH-receptor activation | No DIN; named in April 2026 advisory |
| BPC-157 | Tissue-repair peptide (not GH axis) | Animal-model healing effects | No DIN; named in 2025 and 2026 advisories |
| TB-500 (Thymosin β-4) | Tissue-repair peptide (not GH axis) | Actin regulation, repair signalling | No DIN; named in April 2026 advisory |
| Somatropin (HGH) | Exogenous recombinant GH | Direct GH replacement | Approved for specific indications; multiple DINs (Genotropin, Norditropin, etc.) |
BPC-157 and TB-500 are commonly grouped with "peptide therapy" but are not GH-axis compounds. They appear here because BC patients researching GH peptides routinely encounter them in the same clinic conversations. (For NAD+, also frequently included in these conversations: NAD+ is a nucleotide, not a peptide, and is covered separately in our NAD+ IV therapy guide.)
Legal Status in Canada & BC
This is the section that has changed the most in the past year, and the section that most marketing-oriented content does not present accurately.
Regulatory framework. Injectable peptides are regulated as prescription drugs in Canada [3]. (Note: the older "Schedule F" terminology is obsolete, as Health Canada replaced Schedule F with the Prescription Drug List in 2013. Both terms refer to the same regulatory status.) For an injectable peptide to be sold legally in Canada, it must hold a Drug Identification Number (DIN) issued by Health Canada and be dispensed through a licensed pharmacy on a valid prescription. Authorized peptide drugs in Canada include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and somatropin under various brand names. None of the GH peptides discussed in this article, including Sermorelin, Ipamorelin, and CJC-1295, currently hold a DIN. Neither do BPC-157 or TB-500.
Health Canada's April 9, 2026 advisory is the most important fact for BC residents to understand. Health Canada explicitly named the following as unauthorized injectable peptide drugs that should not be purchased or used: BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, HGH and HGH Fragment, Ipamorelin, KPV, Melanotan I and II, MOTS-C, NAD+, SS-31, TB-500, and Retatrutide [1]. Health Canada had previously seized unauthorized peptides from suppliers including Prime Research (Quebec) in April 2025 and Canada Peptide more recently [2,4].
The "research chemical" loophole is closing. Many suppliers have historically sold these peptides labeled "for research purposes only" or "not for human use." This labeling does not change their legal status. Health Canada's advisories make clear that these products are unauthorized drugs regardless of labeling, and purchasing them for personal injection carries legal and health risks.
Provincial enforcement. The College of Physicians and Surgeons of British Columbia (CPSBC) has begun issuing guidance to physicians regarding peptide prescribing. While enforcement has historically focused on suppliers rather than individual patients, physicians who prescribe unauthorized peptides may face professional discipline.
What remains legal. Somatropin (HGH) with a valid DIN, such as Genotropin, Norditropin, Humatrope, Saizen, and Omnitrope, remains legal when prescribed for approved indications and dispensed through a licensed pharmacy.
Approved Indications for HGH in Canada
Human growth hormone is not approved for general anti-aging use in Canada. Health Canada has approved somatropin for specific medical conditions:
- Adult growth hormone deficiency (AGHD) confirmed by stimulation testing
- Pediatric growth hormone deficiency
- Turner syndrome
- Prader-Willi syndrome
- Chronic renal insufficiency in children
- Short stature in children born small for gestational age (SGA)
- Idiopathic short stature in children
For adult patients, AGHD diagnosis typically requires two failed stimulation tests (insulin tolerance test, glucagon stimulation test, or GHRH-arginine test) plus clinical symptoms and low IGF-1 levels. This is a high bar, and most adults seeking "optimization" will not meet diagnostic criteria.
What the Evidence Actually Shows
Sermorelin: The most human data exists for sermorelin, which was FDA-approved in the US as Geref Diagnostic (for diagnostic use) and briefly as Geref (for treatment). Studies from the 1990s showed modest increases in IGF-1 and improvements in body composition in GH-deficient adults. However, the treatment formulation was discontinued due to supply issues, not safety concerns. No current DIN exists in Canada.
Ipamorelin and CJC-1295: These compounds have limited published human trial data. Most evidence comes from small, short-term studies or preclinical research. The combination (often called "Ipamorelin/CJC-1295" or "CJC-1295 with DAC") is popular in wellness clinics but lacks robust clinical trials demonstrating long-term safety or efficacy.
BPC-157: Despite widespread marketing claims, BPC-157 has no published human clinical trials. All evidence comes from animal models, primarily rodent studies of wound healing and tissue repair. Extrapolating these results to humans is scientifically inappropriate.
TB-500: Similar to BPC-157, TB-500 (thymosin beta-4) evidence is primarily preclinical. Some human trials have examined thymosin beta-4 for wound healing, but these used pharmaceutical-grade formulations under controlled conditions, not "research peptides."
Somatropin (HGH): Exogenous HGH has extensive human trial data for approved indications. In adults with confirmed GHD, treatment improves body composition, bone density, quality of life, and potentially cardiovascular markers. However, side effects include fluid retention, joint pain, carpal tunnel syndrome, glucose intolerance, and theoretical concerns about cancer risk with long-term use.
How to Access GH Therapy Legally in BC
For BC residents seeking legitimate growth hormone optimization, the pathway is straightforward but has clear limitations.
Step 1: Medical evaluation. Consult a physician, either your family doctor or an endocrinologist, to discuss symptoms. Common symptoms of adult GHD include fatigue, decreased muscle mass, increased body fat (especially abdominal), reduced bone density, and impaired quality of life.
Step 2: Diagnostic testing. If clinical suspicion exists, your physician may order IGF-1 levels and potentially stimulation testing. Meeting diagnostic criteria for AGHD is necessary for a legal HGH prescription.
Step 3: Prescription and pharmacy. If diagnosed with AGHD, your physician can prescribe somatropin. The prescription must be filled at a licensed Canadian pharmacy. Expect costs of $800 to $2,000+ per month depending on dose and brand, as coverage varies by private insurance plan.
What about private clinics? Some private clinics in BC advertise "peptide therapy" or "hormone optimization." Before engaging with any clinic, ask directly: Does this clinic prescribe only DIN-approved medications dispensed through licensed pharmacies? If the answer involves compounding pharmacies shipping from the US, "research peptides," or products without DINs, the clinic is operating outside Health Canada's regulatory framework.
Frequently Asked Questions
Are GH peptides legal in BC in 2026?
No. GH peptides including Ipamorelin, CJC-1295, and Sermorelin do not hold Drug Identification Numbers in Canada and are classified as unauthorized drugs by Health Canada. The April 2026 Health Canada advisory explicitly named several of these peptides as products that should not be purchased or used. Only somatropin (HGH) with a valid DIN is legal when prescribed for approved indications.
Can I buy peptides online and have them shipped to BC?
Purchasing injectable peptides from online suppliers and having them shipped to BC carries both legal and health risks. Health Canada has seized products from multiple peptide suppliers and classifies these as unauthorized drugs regardless of "research chemical" labeling. Products may also be contaminated, mislabeled, or improperly stored, creating additional safety concerns.
How much does legal HGH therapy cost in BC?
Somatropin (HGH) prescribed for diagnosed adult growth hormone deficiency typically costs $800 to $2,000 or more per month in BC, depending on dosage and brand. Some private insurance plans provide partial coverage for approved indications. MSP does not cover HGH for adults. Consult your insurance provider for specific coverage details.
Do I need a referral to see an endocrinologist for growth hormone testing in BC?
Yes, in most cases. Endocrinologists in BC typically require a referral from a family physician or nurse practitioner. Your referring provider can order initial IGF-1 testing before the referral. Wait times for endocrinology appointments vary by health authority but may be several months. For help navigating referrals, call HealthLinkBC at 8-1-1.
What is the difference between GH peptides and HGH?
GH peptides (secretagogues) stimulate your pituitary gland to release its own growth hormone, preserving natural pulsatile release patterns. HGH (somatropin) is synthetic human growth hormone injected directly, bypassing the pituitary entirely. HGH produces stronger effects but carries higher risks of side effects and suppression of natural GH production. In Canada, only HGH has approved indications and legal DIN-holding products.
Can a naturopath prescribe peptides in BC?
No. Naturopathic doctors in BC cannot prescribe injectable peptides or human growth hormone. These are prescription drugs under federal regulation, and only physicians (MDs), nurse practitioners, and in some cases pharmacists with expanded authority can prescribe them. Additionally, GH peptides without DINs cannot be legally prescribed by any practitioner in Canada.
What are the side effects of HGH therapy?
Common side effects of somatropin (HGH) therapy include fluid retention, joint pain, carpal tunnel syndrome, muscle pain, and elevated blood glucose. More serious concerns include potential effects on cancer risk with long-term use, though evidence is mixed. Side effects are dose-dependent, and medical monitoring is essential. Always discuss risks with your prescribing physician.
Are there legal alternatives to GH peptides for anti-aging in BC?
Evidence-based approaches to healthy aging that are legal and supported by research include regular resistance training (which naturally increases GH pulses), adequate sleep (GH is released primarily during deep sleep), protein-sufficient nutrition, and management of metabolic health. For specific concerns about aging or body composition, consult a qualified healthcare professional who can recommend evidence-based interventions.
References
[1] Health Canada. Safety alert: Unauthorized injectable peptide drugs. April 9, 2026.
[2] Health Canada. Recall and safety alert: Unauthorized health products seized from Prime Research. April 2025.
[3] Health Canada. Prescription Drug List. Current version.
[4] Health Canada. Unauthorized health products seized from Canada Peptide. 2026.
Health Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. For health information and advice, call HealthLinkBC at 8-1-1.